Qiang Liu
Gründer bei Tangent Capital, Inc.
Profil
Qiang Liu is the founder of Tangent Capital, Inc. (founded in 2006) and holds the title of Managing Director.
He is currently a Director at China Nuokang Bio-Pharmaceutical, Inc. (since 2006).
Mr. Liu was previously the President of BCTech Investments, Inc. (2007-2008).
He holds an MBA from York University (2000), a graduate degree from The University of New South Wales (1996), and an undergraduate degree from Jilin University (1989).
Aktive Positionen von Qiang Liu
Unternehmen | Position | Beginn |
---|---|---|
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | Direktor/Vorstandsmitglied | 23.11.2009 |
Tangent Capital, Inc. | Gründer | 13.12.2010 |
Ehemalige bekannte Positionen von Qiang Liu
Unternehmen | Position | Ende |
---|---|---|
BCTech Investments, Inc. | Präsident | 01.12.2008 |
Ausbildung von Qiang Liu
Jilin University | Undergraduate Degree |
The University of New South Wales | Graduate Degree |
York University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | Health Technology |
Tangent Capital, Inc. | |
BCTech Investments, Inc. |